FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 180 filers reported holding FATE THERAPEUTICS INC in Q2 2024. The put-call ratio across all filers is 0.93 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $74,300 | -50.6% | 13,035 | -12.6% | 0.11% | -43.8% |
| Q4 2022 | $150,462 | -64.6% | 14,912 | -21.3% | 0.19% | -54.1% |
| Q3 2022 | $425,000 | -12.0% | 18,946 | -2.7% | 0.42% | -5.9% |
| Q2 2022 | $483,000 | -39.8% | 19,474 | -5.9% | 0.44% | +1.8% |
| Q1 2022 | $802,000 | -15.0% | 20,697 | +28.3% | 0.44% | +32.9% |
| Q4 2021 | $944,000 | +9.9% | 16,138 | +11.3% | 0.33% | +14.3% |
| Q3 2021 | $859,000 | -57.3% | 14,494 | -37.6% | 0.29% | -61.2% |
| Q2 2021 | $2,014,000 | +11.7% | 23,211 | +6.1% | 0.74% | -8.1% |
| Q1 2021 | $1,803,000 | -15.3% | 21,867 | -6.6% | 0.80% | -23.0% |
| Q4 2020 | $2,128,000 | – | 23,407 | – | 1.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $11,083,330 | 2.77% |
| Redmile Group, LLC | 13,169,057 | $43,194,507 | 2.61% |
| SUPERSTRING CAPITAL MANAGEMENT LP | 497,360 | $1,631,341 | 2.06% |
| Boxer Capital, LLC | 8,215,910 | $26,948,185 | 1.42% |
| Deep Track Capital, LP | 5,572,607 | $18,278,151 | 0.55% |
| Vestal Point Capital, LP | 2,000,000 | $6,560,000 | 0.49% |
| Bruce & Co., Inc. | 300,000 | $984,000 | 0.32% |
| Octagon Capital Advisors LP | 520,800 | $1,708,224 | 0.27% |
| Integral Health Asset Management, LLC | 850,000 | $2,788,000 | 0.26% |
| Bellevue Group AG | 4,839,779 | $15,874,475 | 0.26% |